Doctor-Founded Perelel Closes $27M Funding Round to Expand Women’s Wellness Product Line

Perelel, a rapidly growing women’s health supplement company founded by a team of medical and wellness experts, has secured $27 million in growth funding, marking a major moment in its evolution from a niche prenatal brand to a comprehensive women’s health platform. The financing round, announced on Thursday, was led by Prelude Growth Partners, with strong continued participation from existing investors including Unilever Ventures, Willow Growth Partners, and Selva Ventures. This infusion of capital underscores investor confidence in Perelel’s science-first approach and its mission to transform how women access and experience targeted nutritional support across different stages of life. Founded by Victoria Thain Gioia, Alex Taylor, and Dr. Banafsheh Bayati, Perelel initially emerged to address a specific gap in the supplement market: the lack of high-quality, evidence-backed prenatal vitamins designed in alignment with the changing physiological needs of women throughout pregnancy. Many supplements at the time were general, not stage-specific, and lacked transparency about clinical validation or ingredient integrity. Perelel sought to redefine this landscape by offering formulations backed by medical expertise, tailored precisely to the trimester or reproductive stage, and rooted in rigorous scientific research. Over time, the company’s vision expanded as the founders recognized a much broader unmet need in the women’s health sector—support that extended far beyond pregnancy. Today, Perelel’s portfolio encompasses a wide spectrum of supplements crafted for different phases of a woman’s life, including fertility support, prenatal and postnatal care, hormone balance, menstrual health, lactation, and everyday wellness needs. By designing products targeted at specific physiological transitions—whether it’s trying to conceive, managing postpartum recovery, or supporting long-term well-being—the brand positions itself as a lifelong partner for women seeking personalized, clinically informed nutrition. The evolution from a prenatal brand to an inclusive women’s health platform has not only broadened its market but also strengthened its identity as a science-led innovator in a crowded supplement landscape. The newly secured $27 million will be used strategically to build on this foundation. Perelel plans to significantly accelerate product research and development, ensuring that its upcoming launches maintain the same level of clinical rigor and medical validation that have become hallmarks of the brand. The company intends to deepen investment in formal clinical trials, an area that co-founder and OB-GYN Dr. Banafsheh Bayati emphasizes as crucial for delivering measurable, trustworthy health outcomes. In an industry often criticized for vague claims and lack of scientific backing, Perelel’s commitment to research helps establish trust with consumers seeking transparency and efficacy. A substantial portion of the funding will also go toward expanding distribution channels. While Perelel has gained strong traction through direct-to-consumer sales, enhanced retail partnerships and broader market penetration will allow the brand to reach millions of new customers. Expansion into larger retail ecosystems, strategic collaborations, and global markets could significantly elevate its visibility and accessibility. Additionally, the company plans to enhance its digital ecosystem, particularly personalized online engagement, educational content, and data-driven tools that help consumers select supplements aligned with their individual needs. By creating a more interactive and informed digital experience, Perelel aims to reinforce consumer trust and build a loyal community centered on knowledge and empowerment. Co-founder Victoria Thain Gioia described the funding as a pivotal step forward in fulfilling Perelel’s long-term vision. She noted that the company has always prioritized science-backed formulations, transparency of ingredients, and thoughtful product curation designed around women’s unique biological requirements. The new investment, she explained, will allow Perelel to scale these principles more rapidly, reaching more women across different life stages while expanding the innovation pipeline that has defined its success thus far. Her statement reflects a mission-driven focus: to offer women reliable wellness solutions that evolve alongside their own health journeys. The company’s expansion comes at a time when the women’s health supplement market is experiencing significant growth worldwide. Rising health awareness, particularly among younger women seeking preventive care, is driving increased interest in supplements tailored to reproductive health, hormonal balance, and holistic wellness. Higher disposable incomes and a growing demand for clean-label, high-quality nutrition products have also contributed to market expansion. Industry analysts estimate that the global women’s health supplement market could surpass $70 billion by 2030, fueled by consumers' preference for scientifically validated, premium products that offer tangible benefits. This shift in consumer behavior aligns directly with Perelel’s philosophy. The brand’s emphasis on clinical research, transparency, and stage-based formulas resonates with women increasingly seeking precision-based, trustworthy solutions. As supplements play a larger role in everyday health routines, brands that demonstrate credibility and invest in actual science—rather than marketing slogans—are emerging as leaders. With its medical advisory board, clinical partnerships, and robust research pipeline, Perelel aims to distinguish itself in this expanding market as a brand that bridges the gap between medical expertise and accessible consumer wellness. Dr. Bayati, speaking on the company’s continued investment in clinical trials, highlighted that long-term scientific validation is essential not only for the brand’s credibility but also for ensuring real-world efficacy. Unlike many supplement companies that rely solely on ingredient-level research, Perelel aims to validate its complete formulations, emphasizing measurable outcomes for women. This level of commitment positions the company uniquely within the supplement space, where rigorous clinical testing is still relatively rare. The funding also enables the company to enhance operational capacity, improve supply chain scalability, and strengthen partnerships with healthcare professionals who often guide women in selecting nutritional supplements during critical life stages. Building stronger connections with doctors, nutritionists, and wellness practitioners will further reinforce Perelel’s role as a trusted resource within the medical community. Looking ahead, the company envisions becoming a comprehensive platform for women’s health needs—a one-stop ecosystem where product innovation, medical insight, digital education, and personalized guidance come together. With women increasingly taking a proactive approach to their health, Perelel aims to support their journeys with solutions that evolve from conception to postpartum to lifelong wellness. With this significant funding milestone, Perelel is poised to solidify its leadership in the research-backed supplement category. As the company continues expanding beyond its prenatal roots, its commitment to science, transparency, and women-centered care remains central. Supported by strong investor confidence and a rapidly growing demand for evidence-driven wellness solutions, Perelel’s next chapter represents not just business growth, but a broader movement toward elevating how women’s health is addressed in the global supplement industry.